Robust manufacturable controller and miniaturized electronics for Total Artificial Hearts
| Reference number | |
| Coordinator | Scandinavian Real Heart AB |
| Funding from Vinnova | SEK 4 000 000 |
| Project duration | July 2024 - June 2026 |
| Status | Ongoing |
| Venture | The strategic innovation programme Electronic Components and Systems: |
| Call | Electronic components & systems - research and innovation projects 2024 |
Purpose and goal
The objective of the project is to use the new cardiovascular simulator developed in the previous project to further evaluate the artificial heart, develop the clinical controller for robust manufacturing, and take the first development steps for a smaller sequel of the artificial heart for patients of smaller body size, mainly women.
Expected effects and result
Comparative data between Realheart TAH and the market-leading competitor to be used for marketing purposes and to increase interest in the company among investors; controller that is more optimized for manufacturing; evaluation of the performance of components critical to size reduction; developed strategy to miniaturize the electronics.
Planned approach and implementation
Realheart TAH and competing product are tested in the new cardiovascular simulator (WP1). In parallel, MINIheart is computer simulated in different digital twins to identify product size and cardiac output (WP2). Then the physiological controller is evaluated and steps to increase robustness and manufacturability are applied (WP3). Then there is parallel testing of new mechanical components critical for size reduction (WP4) and strategies to miniaturize the electronics (WP5). Project management, IP, equality work, dissemination of results are continuous throughout project.